IncellDx, Inc. Signs Exclusive License with Claremont BioSolutions to Commercialize Novel Liquid-Based Biopsy Technology
- Companies’ Combined Technology Produces a “Universal” Sample from Liquid, Fresh or Formalin-Fixed Paraffin Embedded (FFPE) Tissue for Multiplexed Cell Analysis by Flow or Image Cytometry
Bruce Patterson, M.D., CEO of IncellDx commented, “This exciting marriage of technologies circumvents the problems of using different technologies for different specimen types by creating a ‘Universal Specimen.’ This will allow IncellDx to compete in the histology and immunohistochemistry (IHC) space with our single cell multiplex technology in cancer and infectious disease.”
“The IncellDx liquid biopsy technology is likely to have a major impact in cancer diagnostics and ClaremontBio is pleased that our unique cell dispersion disposables will help to make that possible,” commented Gary Blackburn, Ph.D., CEO of Claremont BioSolutions.
About IncellDx, Inc.
IncellDx, Inc. (www.incelldx.com) is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, lung cancer, HIV/AIDS, hepatitis, and organ transplant rejection. For more information, please visit our website.
About Claremont BioSolutions, LLC.
Claremont BioSolutions (www.ClaremontBio.com) is a privately held, emerging growth technology company specializing in miniaturized, disposable devices and instruments that provide solutions to what is recognized as the “bottleneck” of DNA diagnostics - sample preparation. The company has developed proprietary disposable devices that employ micro-motors to perform very efficient mechanical tissue homogenization, cell lysis, and nucleic acid extraction.
Website: http://www.incelldx.com
Contact
for IncellDx
Eric Hass
650-777-7630
This news is a press release provided by IncellDx, Inc..
-
2018년 1월 18일 13:40